LEADER 05610nam 22007695 450 001 9910300229103321 005 20251116134608.0 010 $a1-60761-424-3 024 7 $a10.1007/978-1-60761-424-1 035 $a(CKB)3710000000413947 035 $a(EBL)2097306 035 $a(SSID)ssj0001501442 035 $a(PQKBManifestationID)11848388 035 $a(PQKBTitleCode)TC0001501442 035 $a(PQKBWorkID)11524390 035 $a(PQKB)10132769 035 $a(DE-He213)978-1-60761-424-1 035 $a(MiAaPQ)EBC2097306 035 $a(PPN)186030878 035 $a(EXLCZ)993710000000413947 100 $a20150511d2015 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aDyslipidemias $ePathophysiology, Evaluation and Management /$fedited by Abhimanyu Garg 205 $a1st ed. 2015. 210 1$aTotowa, NJ :$cHumana Press :$cImprint: Humana,$d2015. 215 $a1 online resource (525 p.) 225 1 $aContemporary Endocrinology,$x2523-3785 300 $aDescription based upon print version of record. 311 08$a1-60761-423-5 320 $aIncludes bibliographical references and index at the end of each chapters. 327 $aLipoprotein Physiology -- Epidemiology of Blood Lipids and Lipoproteins -- Lipoprotein(a) -- Lipoproteins and Cardiovascular Disease Risk -- Detection and Treatment of Children and Adolescents with Dyslipidemia -- Type 2 Diabetes Mellitus and Dyslipidemia -- Type 1 Diabetes Mellitus and Dyslipidemia -- Dyslipidemia in Chronic Kidney Disease and Nephrotic Syndrome -- Dyslipidemia in HIV-infected Patients -- Monogenic Hypercholesterolemia -- Primary Hypertriglyceridemia -- Genetic Disorders of HDL Metabolism -- Sitosterolemia and Other Rare Sterol Disorders -- Genetic Abetalipoproteinemia & Hypobetalipoproteinemia -- Drug-induced Dyslipidemia -- Lipodystrophies and Dyslipidemias -- Novel Genes for Dyslipidemias: Genome-Wide Association Studies -- Perspectives on Cholesterol Guidelines -- Nutrition and Coronary Heart Disease Prevention -- Phytosterol Therapy -- N-3 Fatty Acids: Role in Treating Dyslipidemias and Preventing Cardiovascular Disease -- Polyphenols for Cholesterol Management -- Dietary Supplements for Cholesterol Management -- Statins: Risk-Benefits and Role in Treating Dyslipidemias -- Fibrates: Risk-Benefits and Role in Treating Dyslipidemias -- Niacin: Risk-Benefits and Role in Treating Dyslipidemias -- Bile Acid Sequestrants: Risk-Benefits and Role in Treating Dyslipidemias -- Cholesterol Absorption Inhibitor-Ezetimibe: Risk-Benefits and Role in Treating Dyslipidemias -- Low Density Lipoprotein (LDL) Apheresis -- Novel Lipid Lowering Agents. 330 $aDyslipidemias: Pathophysiology, Evaluation and Management provides a wealth of general and detailed guidelines for the clinical evaluation and management of lipid disorders in adults and children.  Covering the full range of common through rare lipid disorders, this timely resource offers targeted, practical information for all clinicians who care for patients with dyslipidemias, including general internists, pediatric and adult endocrinologists, pediatricians, lipidologists, cardiologists, internists, and geneticists.  For the last twenty years, there has been a growing recognition worldwide of the importance of managing dyslipidemia for the primary and secondary prevention of atherosclerotic vascular disease, especially coronary heart disease. This has been mainly due to the publication of the guidelines of National Cholesterol Education Program?s Adult Treatment Panel and Pediatric Panel from the United States. These guidelines have stimulated generation of similar recommendations from all over the world, particularly Europe, Canada, Australia and Asia.  Developed by a renowned group of leading international experts, the book offers state-of-the-art chapters that are peer-reviewed and represent a comprehensive assessment of the field.  A major addition to the literature, Dyslipidemias: Pathophysiology, Evaluation and Management is a gold-standard level reference for all clinicians who are challenged to provide the best care and new opportunities for patients with dyslipidemias. 410 0$aContemporary Endocrinology,$x2523-3785 606 $aEndocrinology 606 $aInternal medicine 606 $aPrimary care (Medicine) 606 $aCardiology 606 $aPediatrics 606 $aEndocrinology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33053 606 $aInternal Medicine$3https://scigraph.springernature.com/ontologies/product-market-codes/H33002 606 $aPrimary Care Medicine$3https://scigraph.springernature.com/ontologies/product-market-codes/H51000 606 $aCardiology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33037 606 $aPediatrics$3https://scigraph.springernature.com/ontologies/product-market-codes/H49006 615 0$aEndocrinology. 615 0$aInternal medicine. 615 0$aPrimary care (Medicine) 615 0$aCardiology. 615 0$aPediatrics. 615 14$aEndocrinology. 615 24$aInternal Medicine. 615 24$aPrimary Care Medicine. 615 24$aCardiology. 615 24$aPediatrics. 676 $a610 676 $a616 676 $a616.12 676 $a616.4 676 $a618.92 702 $aGarg$b Abhimanyu$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910300229103321 996 $aDyslipidemias$91761787 997 $aUNINA